Date       Wednesday, 01/06/2022
Time       9:00 AM
To          Committee Members
At          Virtual via Microsoft Teams
Subject     AWERB 3Rs Committee

In Attendance:

Apologies:

Minutes – Approved

1. Minutes

2. Matters Arising
   The committee discussed meeting in person in July. It was decided the meeting would be in person
   depending on peoples availability.

3. Retrospective Reviews
   The committee discussed the following:
   - Provision of an outsourced drug discovery platform for diseases with
     an inflammatory component
     Section 2.2; Animals reported in the severe section of table 2.1 for the protocol 5 and 15 were not
     reported. Section 2.9; question (d), confirm the answer “no” is correct. Section 3.2; all the methods
     used for the reduction of animals should be listed. Section 3.7; Are all refinement methods
     applicable to all animal strains. Section 4.9; investigate any possibilities of public outreach without
     breaching confidentiality agreements
   - Autophagy and other modulators of proteinopathies
     Section 2.2; animals reported in the severe section of table 2.1 but no other information was
     provided. Section 2.7; what is the percentage of wastage due to the double transgenic breeding
     strategy. Section 2.10; clarify the use of the red light pattern for Parkinson model, are the animals
     constantly in red light or in reverse lighting. Section 3.2; clarify how the technique allowed a
     reduction of the use of animals. Section 3.8; Provide details on the neurodegenerative mice model,
     what is the duration of amplitude of weight loss before these animals are culled. Section 3.9;
     clarification about the humane endpoint associated with the body score condition.
- Mechanisms of tumour development and treatment resistance
Section 2.2; nineteen animals were reported in the severe section of table 2.1. were any SC18 reports were submitted? Section 2.7; section to be reworded to emphasis the University was not closed but only essential activities were carried out to maintain animal welfare. Section 2.9; provide more details about how the sharing of animals with external researchers was achieved. Section 3.2; provide more details in this section.

4. Retrospective assessments

- Cell proliferation, death and cell senescence in cardiovascular disease
Section 2.1; Majority of the animals reported in the moderate section of the table. Has the PPLh considered lowering the severity band of the protocols in the new PPL. Section 2.4; reasons for culling should be stated. Section 2.11; provide details about the sources for outsourced animals. Section 3.3; tools for the purpose of sharing were distributed. It was advised that the 3Rs enquiries list information be recirculated to them

5. Severe Severity

6. Severe Severity licence reviews

7. Standard condition 18 reports
- 25 new SC18 reports submitted since last AWERB 3Rs meeting – No Comments

8. 3Rs information/reports

- NC3Rs Self-Assessment Tool/3Rs strategy –

- *NC3RS/Events – Events | NC3Rs; ones to note include NC3Rs/MRC joint webinar: using both sexes in animal experiments Thurs 21st July 10-11am; Workshop: Anaesthesia and Perioperative care of laboratory rodents and rabbits, Monday 26th Sept – Tues 27th Sept; Workshop: Recognition, prevention and alleviation of pain and distress in laboratory animals, Monday 21st Nov – Fri 25th Nov. Events | NC3Rs

- *Papers of interest/informative documents (attached)

asked if the attached documents can go on the the UBS website. will consult with

9. Highlights of AWERB Standing meeting*

10. Highlights of January AOC meeting*

11. Any Other Business

12. For information only

Date of next meeting: 6th July 2022 in

*Items for information only unless un-starred by committee member